08:00 Tue 15 Oct 2019
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Details of Verona Pharma’s oral presentation are listed below and via the CHEST website here.
Oral Presentation/Poster: Poster E1037 – Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
Presenter:
Session: 4331 Electronic Posters 4
Date / Time: Monday, October 21, 2019 at
Location:
About COPD
COPD is a progressive and life-threatening respiratory disease without a cure. The
About Ensifentrine
Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharma’s prior Phase 2 clinical studies in patients with moderate-to-severe COPD. In addition, nebulized ensifentrine showed further improved lung function and reduced lung volumes in patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. Ensifentrine has been well tolerated in clinical trials involving more than 800 people to date.
About
For more information, please visit veronapharma.com
Forward-Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, the development of ensifentrine, the progress and timing of clinical trials and data, estimates of medical costs for COPD and its status as a leading cause of death worldwide, ensifentrine as a first-in-class phosphodiesterase 3 and 4 inhibitor, and plans to develop ensifentrine for the treatment of cystic fibrosis and asthma.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts and the completion of our Phase 2b trial; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the
For further information, please contact:
Tel: +44 (0)20 3283 4200 | |
info@veronapharma.com | |
N+1 Singer (Nominated Adviser and | Tel: +44 (0)20 3283 4200 |
(European Media and Investor Enquiries) | Tel: +44 (0)20 950 9144 verona@optimumcomms.com |
Mary Clark / | |
(US Investor enquiries) | Tel: +1 212-600-1902 verona@argotpartners.com |
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE